Payment overview · 2025
General Payments
$3,724.18
122 reported records · 29 companies
Healthcare provider profile · identity verified
Vagharshak M Pilossyan, M.D.
Allopathic & Osteopathic Physicians|Internal Medicine · VAN NUYS, CA · NPI 1467530121
Verified facts
What the public records show
CMS Open Payments records show Vagharshak M Pilossyan, M.D. received $3,724.18 in general payments during 2025 across 122 reported records.
Amgen Inc. accounted for 16.5% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 37 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Creon, Eliquis, Gemtesa, Kerendia, Linzess, Mounjaro, Nurtec Odt, Rexulti, Trintellix, Ubrelvy, Zenpep.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported CREON as an associated drug or biological on 91561 records involving 20616 distinct recipient NPIs. Public Medicare Part D data also shows 422 claims for Creon by this doctor in 2024.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported LINZESS as an associated drug or biological on 87954 records involving 21815 distinct recipient NPIs. Public Medicare Part D data also shows 915 claims for Linzess by this doctor in 2024.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SYNTHROID as an associated drug or biological on 10655 records involving 4881 distinct recipient NPIs. Public Medicare Part D data also shows 36 claims for Synthroid by this doctor in 2024.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported UBRELVY as an associated drug or biological on 299803 records involving 61203 distinct recipient NPIs. Public Medicare Part D data also shows 45 claims for Ubrelvy by this doctor in 2024.
Aimmune Therapeutics, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ZENPEP as an associated drug or biological on 32144 records involving 12432 distinct recipient NPIs. Public Medicare Part D data also shows 160 claims for Zenpep by this doctor in 2024.
Amgen Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported PROLIA as an associated drug or biological on 20867 records involving 11744 distinct recipient NPIs. Public Medicare Part D data also shows 30 claims for Prolia by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported BRILINTA as an associated drug or biological on 993 records involving 512 distinct recipient NPIs. Public Medicare Part D data also shows 79 claims for Brilinta by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported FARXIGA as an associated drug or biological on 106133 records involving 42906 distinct recipient NPIs. Public Medicare Part D data also shows 710 claims for Farxiga by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported LOKELMA as an associated drug or biological on 6897 records involving 4326 distinct recipient NPIs. Public Medicare Part D data also shows 25 claims for Lokelma by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported NEXIUM as an associated drug or biological on 464 records involving 299 distinct recipient NPIs. Public Medicare Part D data also shows 49 claims for Nexium by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SYMBICORT as an associated drug or biological on 71 records involving 51 distinct recipient NPIs. Public Medicare Part D data also shows 26 claims for Symbicort by this doctor in 2024.
Bayer Healthcare Pharmaceuticals Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Kerendia as an associated drug or biological on 138674 records involving 48458 distinct recipient NPIs. Public Medicare Part D data also shows 285 claims for Kerendia by this doctor in 2024.
E.R. Squibb & Sons, L.L.C. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ELIQUIS as an associated drug or biological on 27956 records involving 14870 distinct recipient NPIs. Public Medicare Part D data also shows 511 claims for Eliquis by this doctor in 2024.
Esperion Therapeutics, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported NEXLIZET as an associated drug or biological on 63 records involving 47 distinct recipient NPIs. Public Medicare Part D data also shows 156 claims for Nexlizet by this doctor in 2024.
GlaxoSmithKline, LLC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TRELEGY ELLIPTA as an associated drug or biological on 131532 records involving 37148 distinct recipient NPIs. Public Medicare Part D data also shows 369 claims for Trelegy Ellipta by this doctor in 2024.
Janssen Biotech, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported XARELTO as an associated drug or biological on 24 records involving 23 distinct recipient NPIs. Public Medicare Part D data also shows 161 claims for Xarelto by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported JARDIANCE as an associated drug or biological on 47708 records involving 23833 distinct recipient NPIs. Public Medicare Part D data also shows 806 claims for Jardiance by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported MOUNJARO as an associated drug or biological on 186719 records involving 66436 distinct recipient NPIs. Public Medicare Part D data also shows 249 claims for Mounjaro by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TRULICITY as an associated drug or biological on 71 records involving 57 distinct recipient NPIs. Public Medicare Part D data also shows 305 claims for Trulicity by this doctor in 2024.
Lundbeck LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported REXULTI as an associated drug or biological on 71829 records involving 25812 distinct recipient NPIs. Public Medicare Part D data also shows 67 claims for Rexulti by this doctor in 2024.
Novartis Pharmaceuticals Corporation reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ENTRESTO as an associated drug or biological on 9346 records involving 6254 distinct recipient NPIs. Public Medicare Part D data also shows 79 claims for Entresto by this doctor in 2024.
Otsuka America Pharmaceutical, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported REXULTI as an associated drug or biological on 160756 records involving 46288 distinct recipient NPIs. Public Medicare Part D data also shows 67 claims for Rexulti by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ELIQUIS as an associated drug or biological on 87112 records involving 36032 distinct recipient NPIs. Public Medicare Part D data also shows 511 claims for Eliquis by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported NURTEC ODT as an associated drug or biological on 217574 records involving 54025 distinct recipient NPIs. Public Medicare Part D data also shows 12 claims for Nurtec Odt by this doctor in 2024.
Sumitomo Pharma America, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported GEMTESA as an associated drug or biological on 61692 records involving 22152 distinct recipient NPIs. Public Medicare Part D data also shows 31 claims for Gemtesa by this doctor in 2024.
Takeda Pharmaceuticals U.S.A., Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TRINTELLIX as an associated drug or biological on 37075 records involving 14402 distinct recipient NPIs. Public Medicare Part D data also shows 70 claims for Trintellix by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| Amgen Inc. | Unresolved — no canonical attribution shown | $613.21 | 16.5% | 5 | 2025 |
| ABBVIE INC. | Unresolved — no canonical attribution shown | $534.57 | 14.3% | 18 | 2025 |
| Novartis Pharmaceuticals Corporation | Unresolved — no canonical attribution shown | $410.43 | 11.0% | 17 | 2025 |
| Ardelyx, Inc. | Unresolved — no canonical attribution shown | $279.29 | 7.5% | 11 | 2025 |
| Regeneron Healthcare Solutions, Inc. | Unresolved — no canonical attribution shown | $269.43 | 7.2% | 10 | 2025 |
| Otsuka America Pharmaceutical, Inc. | Unresolved — no canonical attribution shown | $176.87 | 4.8% | 10 | 2025 |
| Edwards Lifesciences Corporation | Unresolved — no canonical attribution shown | $157.33 | 4.2% | 1 | 2025 |
| Bayer Healthcare Pharmaceuticals Inc. | Unresolved — no canonical attribution shown | $143.03 | 3.8% | 7 | 2025 |
| Esperion Therapeutics, Inc. | Unresolved — no canonical attribution shown | $118.72 | 3.2% | 5 | 2025 |
| Aimmune Therapeutics, Inc. | Unresolved — no canonical attribution shown | $111.04 | 3.0% | 4 | 2025 |
| Verona Pharma, Inc. | Unresolved — no canonical attribution shown | $109.63 | 2.9% | 4 | 2025 |
| Sumitomo Pharma America, Inc. | Unresolved — no canonical attribution shown | $97.15 | 2.6% | 4 | 2025 |
| Corcept Therapeutics | Unresolved — no canonical attribution shown | $87.06 | 2.3% | 3 | 2025 |
| AstraZeneca Pharmaceuticals LP | Unresolved — no canonical attribution shown | $83.20 | 2.2% | 3 | 2025 |
| Lilly USA, LLC | Unresolved — no canonical attribution shown | $81.66 | 2.2% | 3 | 2025 |
| Janssen Biotech, Inc. | Unresolved — no canonical attribution shown | $62.33 | 1.7% | 2 | 2025 |
| ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | Unresolved — no canonical attribution shown | $60.94 | 1.6% | 2 | 2025 |
| E.R. Squibb & Sons, L.L.C. | Unresolved — no canonical attribution shown | $41.18 | 1.1% | 2 | 2025 |
| UCB, Inc. | Unresolved — no canonical attribution shown | $38.92 | 1.1% | 1 | 2025 |
| Phathom Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $33.81 | 0.9% | 1 | 2025 |
| Axsome Therapeutics, Inc. | Unresolved — no canonical attribution shown | $27.94 | 0.8% | 1 | 2025 |
| PFIZER INC. | Unresolved — no canonical attribution shown | $27.49 | 0.7% | 1 | 2025 |
| GlaxoSmithKline, LLC. | Unresolved — no canonical attribution shown | $27.14 | 0.7% | 1 | 2025 |
| Eisai Inc. | Unresolved — no canonical attribution shown | $25.41 | 0.7% | 1 | 2025 |
| Takeda Pharmaceuticals U.S.A., Inc. | Unresolved — no canonical attribution shown | $24.70 | 0.7% | 1 | 2025 |
| Lundbeck LLC | Unresolved — no canonical attribution shown | $24.36 | 0.7% | 1 | 2025 |
| Kowa Pharmaceuticals America, Inc. | Unresolved — no canonical attribution shown | $23.53 | 0.6% | 1 | 2025 |
| Abbott Laboratories | Unresolved — no canonical attribution shown | $18.81 | 0.5% | 1 | 2025 |
| SHIELD THERAPEUTICS INC | Unresolved — no canonical attribution shown | $15.00 | 0.4% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $3,724.18 | 122 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| EVENITY Normalized: evenity |
Biological | Amgen Inc. | $588.46 | 4 | 2025 |
Source payment records
|
|||||
| QULIPTA Normalized: qulipta |
Drug | ABBVIE INC. | $308.55 | 5 | 2025 |
Source payment records
|
|||||
| IBSRELA Normalized: ibsrela |
Drug | Ardelyx, Inc. | $279.29 | 11 | 2025 |
Source payment records
|
|||||
| DUPIXENT Normalized: dupixent |
Biological | Regeneron Healthcare Solutions, Inc. | $269.43 | 10 | 2025 |
Source payment records
|
|||||
| COSENTYX Normalized: cosentyx |
Drug | Novartis Pharmaceuticals Corporation | $255.71 | 9 | 2025 |
Source payment records
|
|||||
| REXULTI Normalized: rexulti |
Drug | Lundbeck LLC, Otsuka America Pharmaceutical, Inc. | $201.23 | 11 | 2025 |
Source payment records
|
|||||
| SAPIEN 3 Ultra RESILIA Normalized: sapien 3 ultra resilia |
Device | Edwards Lifesciences Corporation | $157.33 | 1 | 2025 |
Source payment records
|
|||||
| LEQVIO Normalized: leqvio |
Drug | Novartis Pharmaceuticals Corporation | $154.72 | 8 | 2025 |
Source payment records
|
|||||
| Kerendia Normalized: kerendia |
Drug | Bayer Healthcare Pharmaceuticals Inc. | $143.03 | 7 | 2025 |
Source payment records
|
|||||
| VRAYLAR Normalized: vraylar |
Drug | ABBVIE INC. | $124.57 | 7 | 2025 |
Source payment records
|
|||||
| NEXLETOL Normalized: nexletol |
Drug | Esperion Therapeutics, Inc. | $118.72 | 5 | 2025 |
Source payment records
|
|||||
| ZENPEP Normalized: zenpep |
Drug | Aimmune Therapeutics, Inc. | $111.04 | 4 | 2025 |
Source payment records
|
|||||
| Ohtuvayre Normalized: ohtuvayre |
Drug | Verona Pharma, Inc. | $109.63 | 4 | 2025 |
Source payment records
|
|||||
| CREON Normalized: creon |
Drug | ABBVIE INC. | $101.45 | 6 | 2025 |
Source payment records
|
|||||
| LINZESS Normalized: linzess |
Drug | ABBVIE INC. | $101.45 | 6 | 2025 |
Source payment records
|
|||||
| GEMTESA Normalized: gemtesa |
Drug | Sumitomo Pharma America, Inc. | $97.15 | 4 | 2025 |
Source payment records
|
|||||
| Korlym Normalized: korlym |
Drug | Corcept Therapeutics | $87.06 | 3 | 2025 |
Source payment records
|
|||||
| BREZTRI Normalized: breztri |
Drug | AstraZeneca Pharmaceuticals LP | $83.20 | 3 | 2025 |
Source payment records
|
|||||
| MOUNJARO Normalized: mounjaro |
Drug | Lilly USA, LLC | $81.66 | 3 | 2025 |
Source payment records
|
|||||
| ZEPBOUND Normalized: zepbound |
Drug | Lilly USA, LLC | $81.66 | 3 | 2025 |
Source payment records
|
|||||
| TREMFYA Normalized: tremfya |
Drug | Janssen Biotech, Inc. | $62.33 | 2 | 2025 |
Source payment records
|
|||||
| CAPLYTA Normalized: caplyta |
Drug | ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | $60.94 | 2 | 2025 |
Source payment records
|
|||||
| UBRELVY Normalized: ubrelvy |
Drug | ABBVIE INC. | $59.59 | 3 | 2025 |
Source payment records
|
|||||
| Bimzelx Normalized: bimzelx |
Biological | UCB, Inc. | $38.92 | 1 | 2025 |
Source payment records
|
|||||
| VOQUEZNA Normalized: voquezna |
Drug | Phathom Pharmaceuticals, Inc. | $33.81 | 1 | 2025 |
Source payment records
|
|||||
| Auvelity Normalized: auvelity |
Drug | Axsome Therapeutics, Inc. | $27.94 | 1 | 2025 |
Source payment records
|
|||||
| NURTEC ODT Normalized: nurtec odt |
Drug | PFIZER INC. | $27.49 | 1 | 2025 |
Source payment records
|
|||||
| ZAVZPRET Normalized: zavzpret |
Drug | PFIZER INC. | $27.49 | 1 | 2025 |
Source payment records
|
|||||
| BENLYSTA Normalized: benlysta |
Biological | GlaxoSmithKline, LLC. | $27.14 | 1 | 2025 |
Source payment records
|
|||||
| COBENFY Normalized: cobenfy |
Drug | E.R. Squibb & Sons, L.L.C. | $25.63 | 1 | 2025 |
Source payment records
|
|||||
| Leqembi Normalized: leqembi |
Drug | Eisai Inc. | $25.41 | 1 | 2025 |
Source payment records
|
|||||
| KRYSTEXXA Normalized: krystexxa |
Biological | Amgen Inc. | $24.75 | 1 | 2025 |
Source payment records
|
|||||
| TRINTELLIX Normalized: trintellix |
Drug | Takeda Pharmaceuticals U.S.A., Inc. | $24.70 | 1 | 2025 |
Source payment records
|
|||||
| ZORYVE Normalized: zoryve |
Drug | Kowa Pharmaceuticals America, Inc. | $23.53 | 1 | 2025 |
Source payment records
|
|||||
| FREESTYLE LIBRE 3 Normalized: freestyle libre 3 |
Device | Abbott Laboratories | $18.81 | 1 | 2025 |
Source payment records
|
|||||
| ELIQUIS Normalized: eliquis |
Drug | E.R. Squibb & Sons, L.L.C. | $15.55 | 1 | 2025 |
Source payment records
|
|||||
| ACCRUFER Normalized: accrufer |
Drug | SHIELD THERAPEUTICS INC | $15.00 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| CREON creon |
2025 | Creon | 2024 | 422 | exact normalized | Medicare Part D |
| ELIQUIS eliquis |
2025 | Eliquis | 2024 | 511 | exact normalized | Medicare Part D |
| GEMTESA gemtesa |
2025 | Gemtesa | 2024 | 31 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| Kerendia kerendia |
2025 | Kerendia | 2024 | 285 | exact normalized | Medicare Part D |
| LINZESS linzess |
2025 | Linzess | 2024 | 915 | exact normalized | Medicare Part D |
| MOUNJARO mounjaro |
2025 | Mounjaro | 2024 | 249 | exact normalized | Medicare Part D |
| NURTEC ODT nurtec odt |
2025 | Nurtec Odt | 2024 | 12 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| REXULTI rexulti |
2025 | Rexulti | 2024 | 67 | exact normalized | Medicare Part D |
| TRINTELLIX trintellix |
2025 | Trintellix | 2024 | 70 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| UBRELVY ubrelvy |
2025 | Ubrelvy | 2024 | 45 | exact normalized | Medicare Part D |
| ZENPEP zenpep |
2025 | Zenpep | 2024 | 160 | exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | CREON open payments reported associated product |
CMS Open Payments — General Payments 91561 supporting records · 20616 recipient NPIs · example record 1201352608 |
Creon · 2024 Exact normalized brand match · 1 Part D row |
422 | 66 |
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | LINZESS open payments reported associated product |
CMS Open Payments — General Payments 87954 supporting records · 21815 recipient NPIs · example record 1201352608 |
Linzess · 2024 Exact normalized brand match · 1 Part D row |
915 | 120 |
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | SYNTHROID open payments reported associated product |
CMS Open Payments — General Payments 10655 supporting records · 4881 recipient NPIs · example record 1201352636 |
Synthroid · 2024 Exact normalized brand match · 1 Part D row |
36 | suppressed by CMS |
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | UBRELVY open payments reported associated product |
CMS Open Payments — General Payments 299803 supporting records · 61203 recipient NPIs · example record 1201352530 |
Ubrelvy · 2024 Exact normalized brand match · 1 Part D row |
45 | 12 |
| Aimmune Therapeutics, Inc. Exact reporting entity; no affiliate inference |
2025 | ZENPEP open payments reported associated product |
CMS Open Payments — General Payments 32144 supporting records · 12432 recipient NPIs · example record 1249641927 |
Zenpep · 2024 Exact normalized brand match · 1 Part D row |
160 | 21 |
| Amgen Inc. Exact reporting entity; no affiliate inference |
2025 | PROLIA open payments reported associated product |
CMS Open Payments — General Payments 20867 supporting records · 11744 recipient NPIs · example record 1226874448 |
Prolia · 2024 Exact normalized brand match · 1 Part D row |
30 | 25 |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | BRILINTA open payments reported associated product |
CMS Open Payments — General Payments 993 supporting records · 512 recipient NPIs · example record 1206131430 |
Brilinta · 2024 Exact normalized brand match · 1 Part D row |
79 | 11 |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | FARXIGA open payments reported associated product |
CMS Open Payments — General Payments 106133 supporting records · 42906 recipient NPIs · example record 1206131362 |
Farxiga · 2024 Exact normalized brand match · 1 Part D row |
710 | 103 |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | LOKELMA open payments reported associated product |
CMS Open Payments — General Payments 6897 supporting records · 4326 recipient NPIs · example record 1206131624 |
Lokelma · 2024 Exact normalized brand match · 1 Part D row |
25 | 12 |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | NEXIUM open payments reported associated product |
CMS Open Payments — General Payments 464 supporting records · 299 recipient NPIs · example record 1206134180 |
Nexium · 2024 Exact normalized brand match · 1 Part D row |
49 | suppressed by CMS |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | SYMBICORT open payments reported associated product |
CMS Open Payments — General Payments 71 supporting records · 51 recipient NPIs · example record 1206132610 |
Symbicort · 2024 Exact normalized brand match · 1 Part D row |
26 | suppressed by CMS |
| Bayer Healthcare Pharmaceuticals Inc. Exact reporting entity; no affiliate inference |
2025 | Kerendia open payments reported associated product |
CMS Open Payments — General Payments 138674 supporting records · 48458 recipient NPIs · example record 1225434663 |
Kerendia · 2024 Exact normalized brand match · 1 Part D row |
285 | 40 |
| E.R. Squibb & Sons, L.L.C. Exact reporting entity; no affiliate inference |
2025 | ELIQUIS open payments reported associated product |
CMS Open Payments — General Payments 27956 supporting records · 14870 recipient NPIs · example record 1184377713 |
Eliquis · 2024 Exact normalized brand match · 1 Part D row |
511 | 63 |
| Esperion Therapeutics, Inc. Exact reporting entity; no affiliate inference |
2025 | NEXLIZET open payments reported associated product |
CMS Open Payments — General Payments 63 supporting records · 47 recipient NPIs · example record 1243951667 |
Nexlizet · 2024 Exact normalized brand match · 1 Part D row |
156 | 30 |
| GlaxoSmithKline, LLC. Exact reporting entity; no affiliate inference |
2025 | TRELEGY ELLIPTA open payments reported associated product |
CMS Open Payments — General Payments 131532 supporting records · 37148 recipient NPIs · example record 1190332369 |
Trelegy Ellipta · 2024 Exact normalized brand match · 1 Part D row |
369 | 64 |
| Janssen Biotech, Inc. Exact reporting entity; no affiliate inference |
2025 | XARELTO open payments reported associated product |
CMS Open Payments — General Payments 24 supporting records · 23 recipient NPIs · example record 1174259978 |
Xarelto · 2024 Exact normalized brand match · 1 Part D row |
161 | 21 |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | JARDIANCE open payments reported associated product |
CMS Open Payments — General Payments 47708 supporting records · 23833 recipient NPIs · example record 1186464557 |
Jardiance · 2024 Exact normalized brand match · 1 Part D row |
806 | 102 |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | MOUNJARO open payments reported associated product |
CMS Open Payments — General Payments 186719 supporting records · 66436 recipient NPIs · example record 1186464455 |
Mounjaro · 2024 Exact normalized brand match · 1 Part D row |
249 | 50 |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | TRULICITY open payments reported associated product |
CMS Open Payments — General Payments 71 supporting records · 57 recipient NPIs · example record 1186464601 |
Trulicity · 2024 Exact normalized brand match · 1 Part D row |
305 | 38 |
| Lundbeck LLC Exact reporting entity; no affiliate inference |
2025 | REXULTI open payments reported associated product |
CMS Open Payments — General Payments 71829 supporting records · 25812 recipient NPIs · example record 1251759986 |
Rexulti · 2024 Exact normalized brand match · 1 Part D row |
67 | 11 |
| Novartis Pharmaceuticals Corporation Exact reporting entity; no affiliate inference |
2025 | ENTRESTO open payments reported associated product |
CMS Open Payments — General Payments 9346 supporting records · 6254 recipient NPIs · example record 1200004797 |
Entresto · 2024 Exact normalized brand match · 1 Part D row |
79 | 14 |
| Otsuka America Pharmaceutical, Inc. Exact reporting entity; no affiliate inference |
2025 | REXULTI open payments reported associated product |
CMS Open Payments — General Payments 160756 supporting records · 46288 recipient NPIs · example record 1227267708 |
Rexulti · 2024 Exact normalized brand match · 1 Part D row |
67 | 11 |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | ELIQUIS open payments reported associated product |
CMS Open Payments — General Payments 87112 supporting records · 36032 recipient NPIs · example record 1228794063 |
Eliquis · 2024 Exact normalized brand match · 1 Part D row |
511 | 63 |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | NURTEC ODT open payments reported associated product |
CMS Open Payments — General Payments 217574 supporting records · 54025 recipient NPIs · example record 1228794063 |
Nurtec Odt · 2024 Exact normalized brand match · 1 Part D row |
12 | suppressed by CMS |
| Sumitomo Pharma America, Inc. Exact reporting entity; no affiliate inference |
2025 | GEMTESA open payments reported associated product |
CMS Open Payments — General Payments 61692 supporting records · 22152 recipient NPIs · example record 1176593503 |
Gemtesa · 2024 Exact normalized brand match · 1 Part D row |
31 | suppressed by CMS |
| Takeda Pharmaceuticals U.S.A., Inc. Exact reporting entity; no affiliate inference |
2025 | TRINTELLIX open payments reported associated product |
CMS Open Payments — General Payments 37075 supporting records · 14402 recipient NPIs · example record 1223616266 |
Trintellix · 2024 Exact normalized brand match · 1 Part D row |
70 | suppressed by CMS |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Atorvastatin Calcium | Atorvastatin Calcium | 3765 | 436 |
| Gabapentin | Gabapentin | 3025 | 345 |
| Omeprazole | Omeprazole | 2778 | 361 |
| Amlodipine Besylate | Amlodipine Besylate | 2534 | 297 |
| Ezetimibe | Ezetimibe | 2320 | 261 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 1874 | 219 |
| Metformin Hcl | Metformin Hcl | 1850 | 220 |
| Vascepa | Icosapent Ethyl | 1834 | 251 |
| Tamsulosin Hcl | Tamsulosin Hcl | 1757 | 199 |
| Carvedilol | Carvedilol | 1703 | 196 |
| Clonidine Hcl | Clonidine Hcl | 1669 | 180 |
| Meclizine Hcl | Meclizine Hcl | 1668 | 218 |
| Metoprolol Tartrate | Metoprolol Tartrate | 1623 | 190 |
| Ibuprofen | Ibuprofen | 1531 | 222 |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 1461 | 169 |
| Alendronate Sodium | Alendronate Sodium | 1398 | 156 |
| Levothyroxine Sodium | Levothyroxine Sodium | 1387 | 160 |
| Nifedipine Er | Nifedipine | 1387 | 159 |
| Hydralazine Hcl | Hydralazine Hcl | 1375 | 146 |
| Sertraline Hcl | Sertraline Hcl | 1247 | 133 |
| Lorazepam | Lorazepam | 1205 | 185 |
| Donepezil Hcl | Donepezil Hcl | 1188 | 125 |
| Fluticasone Propionate | Fluticasone Propionate | 1137 | 342 |
| Icosapent Ethyl | Icosapent Ethyl | 1106 | 217 |
| Dexlansoprazole Dr | Dexlansoprazole | 1093 | 173 |
| Olmesartan-Hydrochlorothiazide | Olmesartan/Hydrochlorothiazide | 1083 | 129 |
| Naproxen | Naproxen | 1027 | 128 |
| Memantine Hcl | Memantine Hcl | 980 | 123 |
| Hydrochlorothiazide | Hydrochlorothiazide | 969 | 101 |
| Celecoxib | Celecoxib | 965 | 125 |
| Zolpidem Tartrate | Zolpidem Tartrate | 942 | 171 |
| Linzess | Linaclotide | 915 | 120 |
| Clonidine | Clonidine | 895 | 96 |
| Spironolactone | Spironolactone | 823 | 88 |
| Jardiance | Empagliflozin | 806 | 102 |
| Ozempic | Semaglutide | 790 | 111 |
| Meloxicam | Meloxicam | 782 | 98 |
| Furosemide | Furosemide | 767 | 121 |
| Fenofibrate | Fenofibrate,micronized | 742 | 83 |
| Metoprolol Succinate | Metoprolol Succinate | 740 | 80 |
| Clopidogrel | Clopidogrel Bisulfate | 727 | 88 |
| Farxiga | Dapagliflozin Propanediol | 710 | 103 |
| Tramadol Hcl | Tramadol Hcl | 698 | 105 |
| Aripiprazole | Aripiprazole | 688 | 80 |
| Losartan Potassium | Losartan Potassium | 685 | 87 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 683 | 198 |
| Ketoconazole | Ketoconazole | 652 | 116 |
| Sumatriptan Succinate | Sumatriptan Succinate | 651 | 65 |
| Pantoprazole Sodium | Pantoprazole Sodium | 649 | 87 |
| Tolterodine Tartrate Er | Tolterodine Tartrate | 638 | 103 |
| Hydrocortisone | Hydrocortisone | 619 | 127 |
| Diclofenac Sodium | Diclofenac Sodium | 618 | 137 |
| Januvia | Sitagliptin Phosphate | 614 | 69 |
| Azithromycin | Azithromycin | 564 | 352 |
| Glimepiride | Glimepiride | 563 | 58 |
| Oxybutynin Chloride Er | Oxybutynin Chloride | 547 | 64 |
| Potassium Chloride | Potassium Chloride | 527 | 97 |
| Eliquis | Apixaban | 511 | 63 |
| Alcohol Prep Pads | Alcohol Antiseptic Pads | 497 | 113 |
| Hydrocodone-Acetaminophen | Hydrocodone/Acetaminophen | 473 | 83 |
| Mirtazapine | Mirtazapine | 467 | 46 |
| Finasteride | Finasteride | 465 | 47 |
| Escitalopram Oxalate | Escitalopram Oxalate | 460 | 48 |
| Esomeprazole Magnesium | Esomeprazole Magnesium | 459 | 73 |
| Simvastatin | Simvastatin | 458 | 51 |
| Enalapril Maleate | Enalapril Maleate | 457 | 49 |
| Myrbetriq | Mirabegron | 450 | 62 |
| Propranolol Hcl | Propranolol Hcl | 443 | 55 |
| Alprazolam | Alprazolam | 435 | 66 |
| Lisinopril | Lisinopril | 432 | 52 |
| Creon | Lipase/Protease/Amylase | 422 | 66 |
| Colchicine | Colchicine | 401 | 44 |
| Montelukast Sodium | Montelukast Sodium | 399 | 44 |
| Amitriptyline Hcl | Amitriptyline Hcl | 397 | 42 |
| Memantine Hcl Er | Memantine Hcl | 389 | 57 |
| Basaglar Kwikpen U-100 | Insulin Glargine,hum.Rec.Anlog | 376 | 74 |
| Janumet | Sitagliptin Phos/Metformin Hcl | 371 | 49 |
| Trelegy Ellipta | Fluticasone/Umeclidin/Vilanter | 369 | 64 |
| Novolog Flexpen | Insulin Aspart | 356 | 81 |
| Valsartan-Hydrochlorothiazide | Valsartan/Hydrochlorothiazide | 355 | 38 |
| Repaglinide | Repaglinide | 331 | 39 |
| Olmesartan Medoxomil | Olmesartan Medoxomil | 327 | 34 |
| Dutasteride | Dutasteride | 325 | 37 |
| Trulicity | Dulaglutide | 305 | 38 |
| Atenolol | Atenolol | 297 | 31 |
| Bupropion Xl | Bupropion Hcl | 290 | 33 |
| Pregabalin | Pregabalin | 286 | 38 |
| Kerendia | Finerenone | 285 | 40 |
| Triamcinolone Acetonide | Triamcinolone Acetonide | 275 | 56 |
| Quetiapine Fumarate | Quetiapine Fumarate | 268 | 32 |
| Alcohol Swabs | Alcohol Antiseptic Pads | 258 | 47 |
| Famotidine | Famotidine | 254 | 32 |
| Fluticasone-Salmeterol | Fluticasone Propion/Salmeterol | 251 | 37 |
| Tradjenta | Linagliptin | 251 | 30 |
| Mounjaro | Tirzepatide | 249 | 50 |
| Amlodipine Besylate-Benazepril | Amlodipine Besylate/Benazepril | 248 | 30 |
| Trazodone Hcl | Trazodone Hcl | 245 | 25 |
| Omega-3 Acid Ethyl Esters | Omega-3 Acid Ethyl Esters | 239 | 51 |
| Diltiazem 24hr Er (Cd) | Diltiazem Hcl | 225 | 27 |
| Ventolin Hfa | Albuterol Sulfate | 219 | 59 |
| Metformin Er Gastric | Metformin Hcl | 216 | 49 |
| Allopurinol | Allopurinol | 213 | 30 |
| Fenofibrate | Fenofibrate | 211 | 42 |
| Glipizide | Glipizide | 210 | 23 |
| Procto-Med Hc | Hydrocortisone | 206 | 41 |
| Benazepril Hcl | Benazepril Hcl | 200 | 24 |
| Tresiba Flextouch U-100 | Insulin Degludec | 199 | 32 |
| Methimazole | Methimazole | 198 | 19 |
| Diclofenac Potassium | Diclofenac Potassium | 197 | 49 |
| Easy Touch Alcohol Prep Pads | Alcohol Antiseptic Pads | 197 | 49 |
| Anoro Ellipta | Umeclidinium Brm/Vilanterol Tr | 189 | 45 |
| Duloxetine Hcl | Duloxetine Hcl | 187 | 18 |
| Dapagliflozin | Dapagliflozin Propanediol | 184 | 53 |
| Nitroglycerin | Nitroglycerin | 177 | 33 |
| Ultra-Fine Nano Pen Needle | Pen Needle, Diabetic | 176 | 42 |
| Ciprofloxacin Hcl | Ciprofloxacin Hcl | 172 | 146 |
| Ranolazine Er | Ranolazine | 171 | 18 |
| Citalopram Hbr | Citalopram Hydrobromide | 169 | 21 |
| Nebivolol Hcl | Nebivolol Hcl | 166 | 23 |
| Xarelto | Rivaroxaban | 161 | 21 |
| Lansoprazole | Lansoprazole | 160 | 29 |
| Zenpep | Lipase/Protease/Amylase | 160 | 21 |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 159 | 39 |
| Nexlizet | Bempedoic Acid/Ezetimibe | 156 | 30 |
| Isosorbide Mononitrate Er | Isosorbide Mononitrate | 154 | 20 |
| Lidocaine | Lidocaine | 153 | 23 |
| Pitavastatin Calcium | Pitavastatin Calcium | 146 | 26 |
| Pioglitazone Hcl | Pioglitazone Hcl | 143 | 14 |
| Meloxicam | Meloxicam, Submicronized | 142 | 25 |
| Baclofen | Baclofen | 140 | 15 |
| Fenofibrate | Fenofibrate Nanocrystallized | 140 | 14 |
| Azelastine Hcl | Azelastine Hcl | 139 | 30 |
| Ultra-Fine Short Pen Needle | Pen Needle, Diabetic | 137 | 27 |
| Betamethasone Diprop Augmented | Betamethasone/Propylene Glyc | 134 | 30 |
| Namzaric | Memantine Hcl/Donepezil Hcl | 132 | 13 |
| Ramipril | Ramipril | 131 | 13 |
| Carbidopa-Levodopa | Carbidopa/Levodopa | 129 | 15 |
| Prednisone | Prednisone | 128 | 107 |
| Dupixent Pen | Dupilumab | 125 | 20 |
| Valsartan | Valsartan | 125 | 15 |
| Clonazepam | Clonazepam | 123 | 18 |
| Pravastatin Sodium | Pravastatin Sodium | 123 | 13 |
| Olmesartan-Amlodipine-Hctz | Olmesartan/Amlodipin/Hcthiazid | 122 | 18 |
| Buspirone Hcl | Buspirone Hcl | 114 | 11 |
| Sulfamethoxazole-Trimethoprim | Sulfamethoxazole/Trimethoprim | 108 | 95 |
| Terazosin Hcl | Terazosin Hcl | 108 | 14 |
| Bumetanide | Bumetanide | 107 | 14 |
| Solifenacin Succinate | Solifenacin Succinate | 107 | 17 |
| Oseltamivir Phosphate | Oseltamivir Phosphate | 104 | 92 |
| Omeprazole-Sodium Bicarbonate | Omeprazole/Sodium Bicarbonate | 98 | 22 |
| Rybelsus | Semaglutide | 98 | 14 |
| Tavaborole | Tavaborole | 98 | 24 |
| Vitamin D2 | Ergocalciferol (Vitamin D2) | 98 | 29 |
| Bupropion Hcl Sr | Bupropion Hcl | 97 | 11 |
| Cilostazol | Cilostazol | 97 | 14 |
| Digoxin | Digoxin | 94 | 11 |
| Ibandronate Sodium | Ibandronate Sodium | 85 | suppressed |
| Olanzapine | Olanzapine | 85 | 11 |
| Admelog Solostar | Insulin Lispro | 82 | 17 |
| Nystatin | Nystatin | 82 | 26 |
| Topiramate | Topiramate | 82 | suppressed |
| Ultra-Fine Micro Pen Needle | Pen Needle, Diabetic | 82 | 19 |
| Ibu | Ibuprofen | 81 | 21 |
| Dexilant | Dexlansoprazole | 80 | 17 |
| Brilinta | Ticagrelor | 79 | 11 |
| Comfort Ez Pen Needle | Pen Needle, Diabetic | 79 | 20 |
| Entresto | Sacubitril/Valsartan | 79 | 14 |
| Janumet Xr | Sitagliptin Phos/Metformin Hcl | 78 | suppressed |
| Paroxetine Hcl | Paroxetine Hcl | 78 | suppressed |
| Clobetasol Propionate | Clobetasol Propionate | 77 | 16 |
| Megestrol Acetate | Megestrol Acetate | 75 | suppressed |
| Ultra-Fine Mini Pen Needle | Pen Needle, Diabetic | 75 | 21 |
| Trintellix | Vortioxetine Hydrobromide | 70 | suppressed |
| Naproxen-Esomeprazole Mag | Naproxen/Esomeprazole Mag | 69 | 16 |
| Warfarin Sodium | Warfarin Sodium | 68 | suppressed |
| Rexulti | Brexpiprazole | 67 | 11 |
| Alcohol Pads | Alcohol Antiseptic Pads | 65 | 20 |
| Acetaminophen-Codeine | Acetaminophen With Codeine | 64 | 12 |
| Mometasone Furoate | Mometasone Furoate | 63 | 14 |
| Amiodarone Hcl | Amiodarone Hcl | 62 | suppressed |
| Chlorzoxazone | Chlorzoxazone | 62 | suppressed |
| Bisoprolol Fumarate | Bisoprolol Fumarate | 61 | suppressed |
| Breo Ellipta | Fluticasone/Vilanterol | 59 | 11 |
| Diphenoxylate-Atropine | Diphenoxylate Hcl/Atropine | 58 | 22 |
| Isosorbide Dinitrate | Isosorbide Dinitrate | 58 | suppressed |
| Glipizide-Metformin | Glipizide/Metformin Hcl | 55 | suppressed |
| Stiolto Respimat | Tiotropium Br/Olodaterol Hcl | 55 | suppressed |
| Clotrimazole | Clotrimazole | 54 | 19 |
| Fluconazole | Fluconazole | 54 | 34 |
| Proctozone-Hc | Hydrocortisone | 54 | 14 |
| Benicar Hct | Olmesartan/Hydrochlorothiazide | 53 | suppressed |
| Fluocinonide | Fluocinonide | 53 | 18 |
| Fluoxetine Hcl | Fluoxetine Hcl | 53 | suppressed |
| Telmisartan | Telmisartan | 53 | suppressed |
| Rivastigmine | Rivastigmine | 52 | suppressed |
| Ondansetron Hcl | Ondansetron Hcl | 50 | 21 |
| Prasugrel Hcl | Prasugrel Hcl | 50 | suppressed |
| Verapamil Hcl | Verapamil Hcl | 50 | suppressed |
| Insulin Aspart Flexpen | Insulin Aspart | 49 | 20 |
| Nexium | Esomeprazole Magnesium | 49 | suppressed |
| Tresiba Flextouch U-200 | Insulin Degludec | 49 | suppressed |
| Diflorasone Diacetate | Diflorasone Diacetate | 48 | suppressed |
| Gemfibrozil | Gemfibrozil | 47 | suppressed |
| Humalog Kwikpen U-100 | Insulin Lispro | 47 | 11 |
| Mupirocin | Mupirocin | 47 | 19 |
| Nano 2nd Gen Pen Needle | Pen Needle, Diabetic | 47 | 17 |
| Benicar | Olmesartan Medoxomil | 46 | suppressed |
| Ropinirole Hcl | Ropinirole Hcl | 46 | suppressed |
| Klor-Con 8 | Potassium Chloride | 45 | 11 |
| Lisinopril-Hydrochlorothiazide | Lisinopril/Hydrochlorothiazide | 45 | suppressed |
| Ubrelvy | Ubrogepant | 45 | 12 |
| Incruse Ellipta | Umeclidinium Bromide | 42 | suppressed |
| Levofloxacin | Levofloxacin | 42 | 39 |
| Oxybutynin Chloride | Oxybutynin Chloride | 41 | suppressed |
| Advair Diskus | Fluticasone Propion/Salmeterol | 40 | 13 |
| Amoxicillin | Amoxicillin | 40 | 34 |
| Benazepril-Hydrochlorothiazide | Benazepril/Hydrochlorothiazide | 40 | suppressed |
| Budesonide-Formoterol Fumarate | Budesonide/Formoterol Fumarate | 40 | 12 |
| Combivent Respimat | Ipratropium/Albuterol Sulfate | 40 | suppressed |
| Diltiazem Hcl | Diltiazem Hcl | 40 | suppressed |
| Oxycodone Hcl | Oxycodone Hcl | 40 | suppressed |
| Cyclosporine | Cyclosporine | 39 | suppressed |
| Pramipexole Dihydrochloride | Pramipexole Di-Hcl | 39 | suppressed |
| Atrovent Hfa | Ipratropium Bromide | 38 | suppressed |
| Doxazosin Mesylate | Doxazosin Mesylate | 38 | suppressed |
| Zileuton Er | Zileuton | 38 | suppressed |
| Metformin Hcl Er | Metformin Hcl | 37 | suppressed |
| Quetiapine Fumarate Er | Quetiapine Fumarate | 37 | suppressed |
| Sucralfate | Sucralfate | 37 | suppressed |
| Ulticare Pen Needle | Pen Needle, Diabetic | 37 | 18 |
| Cartia Xt | Diltiazem Hcl | 36 | suppressed |
| Metronidazole | Metronidazole | 36 | 16 |
| Synthroid | Levothyroxine Sodium | 36 | suppressed |
| Telmisartan-Hydrochlorothiazid | Telmisartan/Hydrochlorothiazid | 36 | suppressed |
| Fesoterodine Fumarate Er | Fesoterodine Fumarate | 35 | suppressed |
| Hydroxyzine Hcl | Hydroxyzine Hcl | 35 | suppressed |
| Temazepam | Temazepam | 35 | suppressed |
| Venlafaxine Hcl Er | Venlafaxine Hcl | 35 | suppressed |
| Ciclopirox | Ciclopirox | 34 | 18 |
| Clotrimazole-Betamethasone | Clotrimazole/Betamethasone Dip | 34 | suppressed |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 34 | suppressed |
| Dicyclomine Hcl | Dicyclomine Hcl | 33 | suppressed |
| Glipizide Er | Glipizide | 33 | suppressed |
| Mirabegron Er | Mirabegron | 33 | 16 |
| Risedronate Sodium | Risedronate Sodium | 33 | suppressed |
| Fiasp Flextouch | Insulin Aspart (Niacinamide) | 32 | 11 |
| Gemtesa | Vibegron | 31 | suppressed |
| Irbesartan-Hydrochlorothiazide | Irbesartan/Hydrochlorothiazide | 31 | suppressed |
| Levetiracetam | Levetiracetam | 31 | suppressed |
| Verapamil Er | Verapamil Hcl | 31 | suppressed |
| Bydureon Bcise | Exenatide Microspheres | 30 | suppressed |
| Fluocinolone Acetonide | Fluocinolone Acetonide | 30 | suppressed |
| Insulin Lispro Kwikpen U-100 | Insulin Lispro | 30 | suppressed |
| Prolia | Denosumab | 30 | 25 |
| Single Use Swab | Alcohol Antiseptic Pads | 30 | 11 |
| Techlite Pen Needle | Pen Needle, Diabetic | 30 | 12 |
| Oxcarbazepine | Oxcarbazepine | 29 | suppressed |
| Tribenzor | Olmesartan/Amlodipin/Hcthiazid | 27 | suppressed |
| Sumatriptan Succ-Naproxen Sod | Sumatriptan Succ/Naproxen Sod | 26 | suppressed |
| Symbicort | Budesonide/Formoterol Fumarate | 26 | suppressed |
| Jentadueto | Linagliptin/Metformin Hcl | 25 | suppressed |
| Levocetirizine Dihydrochloride | Levocetirizine Dihydrochloride | 25 | suppressed |
| Lokelma | Sodium Zirconium Cyclosilicate | 25 | 12 |
| Niacin Er | Niacin | 25 | suppressed |
| Ssd | Silver Sulfadiazine | 25 | 20 |
| Cholestyramine | Cholestyramine (With Sugar) | 24 | suppressed |
| Econazole Nitrate | Econazole Nitrate | 24 | suppressed |
| Epinephrine | Epinephrine | 24 | suppressed |
| Levemir Flexpen | Insulin Detemir | 24 | suppressed |
| Naproxen Sodium | Naproxen Sodium | 24 | suppressed |
| Ultra-Fine Original Pen Needle | Pen Needle, Diabetic | 24 | suppressed |
| Lotrel | Amlodipine Besylate/Benazepril | 23 | suppressed |
| Lubiprostone | Lubiprostone | 23 | suppressed |
| Ofloxacin | Ofloxacin | 23 | 20 |
| Ezetimibe-Simvastatin | Ezetimibe/Simvastatin | 22 | suppressed |
| Metoclopramide Hcl | Metoclopramide Hcl | 22 | suppressed |
| Spiriva Handihaler | Tiotropium Bromide | 22 | suppressed |
| Toujeo Solostar | Insulin Glargine,hum.Rec.Anlog | 22 | suppressed |
| Valacyclovir | Valacyclovir Hcl | 22 | 21 |
| Breztri Aerosphere | Budesonide/Glycopyr/Formoterol | 21 | suppressed |
| Novofine 32 | Pen Needle, Diabetic | 21 | suppressed |
| Acarbose | Acarbose | 20 | suppressed |
| Alfuzosin Hcl Er | Alfuzosin Hcl | 20 | suppressed |
| Alogliptin | Alogliptin Benzoate | 20 | suppressed |
| Dabigatran Etexilate | Dabigatran Etexilate Mesylate | 20 | suppressed |
| Glyburide-Metformin Hcl | Glyburide/Metformin Hcl | 20 | suppressed |
| Lantus | Insulin Glargine,hum.Rec.Anlog | 20 | suppressed |
| Nitrofurantoin Mono-Macro | Nitrofurantoin Monohyd/M-Cryst | 20 | 15 |
| Primidone | Primidone | 20 | suppressed |
| Amlodipine-Olmesartan | Amlodipine Bes/Olmesartan Med | 19 | suppressed |
| Belsomra | Suvorexant | 19 | suppressed |
| Betamethasone Dipropionate | Betamethasone Dipropionate | 19 | suppressed |
| Diltiazem 12hr Er | Diltiazem Hcl | 19 | suppressed |
| Dutasteride-Tamsulosin | Dutasteride/Tamsulosin Hcl | 19 | suppressed |
| Movantik | Naloxegol Oxalate | 19 | suppressed |
| Permethrin | Permethrin | 19 | 12 |
| Varenicline Tartrate | Varenicline Tartrate | 19 | suppressed |
| Captopril | Captopril | 18 | suppressed |
| Indapamide | Indapamide | 18 | suppressed |
| Labetalol Hcl | Labetalol Hcl | 18 | suppressed |
| Lactulose | Lactulose | 18 | suppressed |
| Repatha Sureclick | Evolocumab | 18 | suppressed |
| Humalog | Insulin Lispro | 17 | suppressed |
| Nystatin-Triamcinolone | Nystatin/Triamcinolone Acet | 17 | suppressed |
| Ondansetron Odt | Ondansetron | 17 | suppressed |
| Spiriva Respimat | Tiotropium Bromide | 17 | suppressed |
| Vytorin | Ezetimibe/Simvastatin | 17 | suppressed |
| Diazepam | Diazepam | 16 | suppressed |
| Haloperidol | Haloperidol | 16 | suppressed |
| Misoprostol | Misoprostol | 16 | suppressed |
| Novolog Mix 70-30 Flexpen | Insulin Aspart Prot/Insuln Asp | 16 | suppressed |
| Pen Needles | Pen Needle, Diabetic | 16 | suppressed |
| Repatha Syringe | Evolocumab | 16 | suppressed |
| Aspirin-Dipyridamole Er | Aspirin/Dipyridamole | 15 | suppressed |
| Bethanechol Chloride | Bethanechol Chloride | 15 | suppressed |
| Carbamazepine | Carbamazepine | 15 | suppressed |
| Cephalexin | Cephalexin | 15 | 14 |
| Metolazone | Metolazone | 15 | suppressed |
| Amoxicillin-Clavulanate Potass | Amoxicillin/Potassium Clav | 14 | 14 |
| Crestor | Rosuvastatin Calcium | 14 | suppressed |
| Fluticasone-Vilanterol | Fluticasone/Vilanterol | 14 | suppressed |
| Halobetasol Propionate | Halobetasol Propionate | 14 | suppressed |
| Insulin Degludec Pen (U-100) | Insulin Degludec | 14 | suppressed |
| Lofena | Diclofenac Potassium | 14 | suppressed |
| Pradaxa | Dabigatran Etexilate Mesylate | 14 | suppressed |
| Synjardy | Empagliflozin/Metformin Hcl | 14 | suppressed |
| Ztlido | Lidocaine | 14 | suppressed |
| Advair Hfa | Fluticasone Propion/Salmeterol | 13 | suppressed |
| Betamethasone Valerate | Betamethasone Valerate | 13 | suppressed |
| Chlorthalidone | Chlorthalidone | 13 | suppressed |
| Ciclopirox | Ciclopirox Olamine | 13 | suppressed |
| Colestipol Hcl | Colestipol Hcl | 13 | suppressed |
| Comfort Ez Insulin Syringe | Syringe And Needle,insulin,1ml | 13 | suppressed |
| Estradiol | Estradiol | 13 | suppressed |
| Humalog Kwikpen U-200 | Insulin Lispro | 13 | suppressed |
| Latanoprost | Latanoprost | 13 | suppressed |
| Lovastatin | Lovastatin | 13 | suppressed |
| Mercaptopurine | Mercaptopurine | 13 | suppressed |
| Nateglinide | Nateglinide | 13 | suppressed |
| Novolin 70-30 | Insulin Nph Hum/Reg Insulin Hm | 13 | suppressed |
| Propranolol Hcl Er | Propranolol Hcl | 13 | suppressed |
| Semglee (Yfgn) Pen | Insulin Glargine-Yfgn | 13 | suppressed |
| Silver Sulfadiazine | Silver Sulfadiazine | 13 | 11 |
| Theophylline Er | Theophylline Anhydrous | 13 | suppressed |
| Verquvo | Vericiguat | 13 | suppressed |
| Acyclovir | Acyclovir | 12 | suppressed |
| Amlodipine-Valsartan | Amlodipine Besylate/Valsartan | 12 | suppressed |
| Cimetidine | Cimetidine | 12 | suppressed |
| Colesevelam Hcl | Colesevelam Hcl | 12 | suppressed |
| Darifenacin Er | Darifenacin Hydrobromide | 12 | suppressed |
| Edarbyclor | Azilsartan Med/Chlorthalidone | 12 | suppressed |
| Exelon | Rivastigmine | 12 | suppressed |
| Galantamine Hbr | Galantamine Hbr | 12 | suppressed |
| Hydrocortisone Butyrate | Hydrocortisone Butyrate | 12 | suppressed |
| Mexiletine Hcl | Mexiletine Hcl | 12 | suppressed |
| Nurtec Odt | Rimegepant Sulfate | 12 | suppressed |
| Plavix | Clopidogrel Bisulfate | 12 | suppressed |
| Raloxifene Hcl | Raloxifene Hcl | 12 | suppressed |
| Alcohol Swab | Alcohol Antiseptic Pads | 11 | suppressed |
| Amantadine | Amantadine Hcl | 11 | suppressed |
| Cabergoline | Cabergoline | 11 | suppressed |
| Ciprofloxacin-Dexamethasone | Ciprofloxacin Hcl/Dexameth | 11 | suppressed |
| Febuxostat | Febuxostat | 11 | suppressed |
| Sure Comfort Alcohol | Alcohol Antiseptic Pads | 11 | suppressed |
| Tiotropium Bromide | Tiotropium Bromide | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $3,724.18 · 122 records | Amgen Inc. | ACCRUFER, Auvelity, BENLYSTA, BREZTRI, Bimzelx, CAPLYTA, COBENFY, COSENTYX, CREON, DUPIXENT, ELIQUIS, EVENITY, FREESTYLE LIBRE 3, GEMTESA, IBSRELA, KRYSTEXXA, Kerendia, Korlym, LEQVIO, LINZESS, Leqembi, MOUNJARO, NEXLETOL, NURTEC ODT, Ohtuvayre, QULIPTA, REXULTI, SAPIEN 3 Ultra RESILIA, TREMFYA, TRINTELLIX, UBRELVY, VOQUEZNA, VRAYLAR, ZAVZPRET, ZENPEP, ZEPBOUND, ZORYVE | 26 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Creon play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with ABBVIE INC.?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error